The phosphate binder ferric citrate coordination complex may mitigate anemia, elevated phosphorus, and FGF23 in patients with advanced CKD, new research suggests.
In a study, the risks for cardiovascular events and all-cause mortality were only a nonsignificant 4% lower for sevelamer vs calcium acetate recipients older than 65 years initiating hemodialysis.
Hemodialysis patients who stayed on the phosphate binder sucroferric oxyhydroxide for 2 years had fewer hospitalizations those who switched to another binder for 2 years.
According to preliminary research, phosphate binders may bind to helpful substances such as vitamin K, but also to harmful ones, such as lipopolysaccharides and advanced glycation end products.
In a small study, vitamin K antagonist use and liver dysfunction emerged as the most important factors in the development of calciphylaxis.
Researchers estimate that half of calcium channel blockers, for example, contain phosphorus as an excipient.
In meta-analyses, elevated FGF23 correlated with 25% and 22% increased risks for all-cause mortality and cardiovascular events, respectively, among patients on maintenance hemodialysis.
In a phase 3 trial, tenapanor, which reduces paracellular phosphate transport in the intestine, lowered elevated serum phosphorus in patients on hemodialysis.
In a new study, patients with serum phosphate levels above 1.78 mmol/L at the start of peritoneal dialysis had a nearly 2-fold increased risk of death.
In a 2-phased trial, hyperphosphatemia and is sequelae developed in a smaller proportion of patients taking activated charcoal compared with placebo recipients.